Immuron us dod naval medical research center receives feedback on ind application for new campylobacter etec therapeutic

Melbourne, australia, july 26, 2022 (globe newswire) -- immuron limited (asx: imc; nasdaq: imrn), an australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutic products for the prevention and treatment of gut pathogens, today announced that the us naval medical research center (nmrc) has received feedback from the us food and drug administration following a review of the investigational new drug (ind) application for a new oral therapeutic targeting campylobacter and etec.
IMRN Ratings Summary
IMRN Quant Ranking